Xeris enters into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a bi-hormonal pump and pump systems. Concord, MA; May 6, 2024 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, […]